Monte Rosa Therapeutics launches patient dosing in MRT-2359 combination study for mCRPC

Traders Union
All News
Business & Wealth
Companies
Monte Rosa starts Phase 2 trial

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

Olga Shendetskaya

24.08.2026

Monte Rosa Therapeutics launches patient dosing in MRT-2359 combination study for mCRPC — Monte Rosa starts Phase 2 trial

Monte Rosa Therapeutics has initiated patient dosing in its Phase 2 MODeFIRe-1 clinical trial. The study is evaluating MRT-2359 in combination with apalutamide for patients with androgen receptor (AR) mutation-positive metastatic castration-resistant prostate cancer (mCRPC).

The start of dosing marks a significant milestone in developing targeted treatments for advanced prostate cancer. The MODeFIRe-1 trial aims to assess both safety and efficacy of the drug combination, potentially opening new therapeutic options for patients with limited alternatives.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Monte Rosa Therapeutics recently released its second quarter financial results for 2026. The company also reported progress across its development pipeline during that period. These updates reflect ongoing efforts to advance clinical-stage candidates for oncology indications.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Who is Richard Heart, the HEX founder wanted by Interpol?

By Olena Litvinenko
6 hours ago

Who is Richard Heart, the HEX founder wanted by Interpol?

Editors' Picks

Kaiko CEO: European stablecoins still cannot compete with USDT

By Eugene Komchuk
8 hours ago

Kaiko CEO: European stablecoins still cannot compete with USDT

Editors' Picks

Adobe and AI: Is the creative software giant losing its edge?

By Dmytro Kharkov
10 hours ago

Adobe and AI: Is the creative software giant losing its edge?

Editors' Picks

All Editors' Top Picks

Latest Monte Rosa News

Monte Rosa Therapeutics to present Phase 1 MRT-8102 data in CVD risk subjects

By Elena Nikulina
30.09.2026

Monte Rosa Therapeutics to present Phase 1 MRT-8102 data in CVD risk subjects

Companies

Monte Rosa Therapeutics delivers second quarter financial results and advances pipeline momentum

By Ashutosh Sureka
06.08.2026

Monte Rosa Therapeutics delivers second quarter financial results and advances pipeline momentum

Companies

Precision oncology approach for CCNE1-altered cancers advances with new data, Monte Rosa Therapeutics reports

By Ashutosh Sureka
22.07.2026

Precision oncology approach for CCNE1-altered cancers advances with new data, Monte Rosa Therapeutics reports

Companies

All Monte Rosa News

Olena Litvinenko
6 hours ago

Who is Richard Heart, the HEX founder wanted by Interpol?

Eugene Komchuk
8 hours ago

Kaiko CEO: European stablecoins still cannot compete with USDT

Dmytro Kharkov
10 hours ago

Adobe and AI: Is the creative software giant losing its edge?

Pavlo Kot
Yesterday

Solana vs. Base: Who will dominate the token launch market?

Pavlo Kot
17.10.2026

Jobs in crypto: Which specialists are in demand now?

Yulia Slavina
11 min ago

Amit Kukreja: Anthropic plans to give 20% of company shares to public, Elon Musk offers $10B in SPCX shares to U.S. children

Elena Nikulina
21 min ago

Dogecoin opportunity was missed in a comical way, Zack Nelson states

Yaroslav Dmytrenko
26 min ago

Traffic should be free until it is unsustainable, Alex Bosworth notes

Oksana Koneva
51 min ago

Ross Gerber: Earnings season brings expectations of 30% increase over estimates

Eugene Komchuk
56 min ago

Caitlin Long: First loan P&I payment to be settled using HazelNetwork tokenized deposit in Dallas event

Top News

Ivan Andriyenko
3 hours ago

Canada inflation comes in below forecasts ahead of central bank decision

Canada inflation comes in below forecasts ahead of central bank decision

Eugene Komchuk
4 hours ago

Trump family's stablecoin loses $400 million in market capitalization

Trump family's stablecoin loses $400 million in market capitalization

Olga Shendetskaya
5 hours ago

Indonesia tightens stock market rules to address MSCI concerns

Indonesia tightens stock market rules to address MSCI concerns

Eugene Komchuk
8 hours ago

Kaiko CEO: European stablecoins still cannot compete with USDT

Kaiko CEO: European stablecoins still cannot compete with USDT

Eugene Komchuk
9 hours ago

JPMorgan launches JPM Coin token on Ethereum

JPMorgan launches JPM Coin token on Ethereum

Top 5 companies for you

United States

Live News

Anton Kharitonov
Now

EUR/USD holds near 1.1230 as ECB and Fed expectations weigh on currency amid Treasury yield stability

Mykhailo Ihnatenko
Now

Nvidia stock tests $217 as AI infrastructure worries pressure tech sector

Parshwa Turakhiya
Now

Crypto.com and Novig challenge Missouri sports betting restrictions

Igor Krasulya
Now

French bond yields face pressure as unrest threatens budget plans

Mykhailo Ihnatenko
Now

Ethereum price prediction: Can ETH break $2,440 before another liquidation wave?

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.